抗ウイルス剤市場レポート：2022-2032

Antiviral Drugs Market Report 2022-2032

レポート詳細抗ウイルス剤市場レポート 2022-2032 :本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く理解する上で、非常に有益なものと... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
Visiongain ヴィジョンゲイン社	2022年11月17日	GBP4,500 部署ライセンスライセンス・価格情報注文方法はこちら	285	322	英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

レポート詳細

抗ウイルス剤市場レポート 2022-2032:本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く理解する上で、非常に有益なものとなるでしょう。また、異業種への進出や新地域での既存事業の拡大を目指す企業にとっても有用なレポートです。

ブロックバスター医薬品の導入が市場成長を後押しする
抗ウイルス剤は、多くの大手製薬会社によって活発に研究開発されています。ギリアド・サイエンスのビクタビやグラクソ・スミスクラインのトリュームなどのブロックバスター薬の登場により、抗レトロウイルス療法は劇的に進化しています。抗ウイルス剤市場の収益は、こうしたブロックバスター薬の消費量の増加と生産者による流通の増加により、2022年から2032年にかけて成長すると予想されます。

COVID-19の流行により、抗ウイルス剤の需要が増加しています。COVID-19の症例が急増し、医療機関がCOVID-19患者の治療に主に力を注いだため、市場が拡大した。さらに、多くの製薬会社が、患者の予後改善とより効果的な治療を提供するために、新薬の開発に力を注いでいた。これらの企業が協力して、期間中、製品の需要に対応しました。

例えば、Johnson & Johnsonは2022年3月、Janssen Pharmaceuticals, Inc.と南アフリカのメーカーAspen SA Operations (Pty) Ltdとの間で歴史的な合意が成立したことを発表しました。大陸全体のCOVID-19の接種率を向上させることを目的とし、これにより、アフリカに居住する人々が使用する初のCOVID-19ワクチンがアフリカの企業によって開発・流通されることになります。このように、市場参加者が積極的に協力し、より多くの患者に対応するために抗ウイルス薬の生産能力を向上させようとする意図的な試みが、すべての抗ウイルス治療薬の市場シェアを押し上げているのです。

製品承認に関する高い厳格性が市場成長の妨げになる可能性が高い

医薬品の製造には、消費者の安全性の観点から、高いレベルのコンプライアンスが要求されます。しかし、コンプライアンスが必要なため、R費用がかさむ。抗ウイルス剤の登録には、製剤の文書化が必要である。抗ウイルス剤にとって比較試験は非常に重要である。文書化、試験、承認要件は国によって異なる。各国の経済的、法的、文化的な事情は、多様なアプローチに影響を与える要素の一つです。

抗ウイルス剤は、製品基準を満たす患者さんに投与された場合、臨床的な有効性が実証されていなければなりません。米国食品医薬品局（FDA）は、簡略化新薬承認申請（ANDA）を受理する必要があります。米国ではFDAが管理しているが、欧州ではEMAが管理している。薬の生物学的同等性は、経口薬の場合、体内における薬物濃度に基づいて証明される。各国には、国内市場で販売する医薬品を認証する規制機関がある。医薬品ビジネスは、多くの国で承認されるよう努力し、さまざまなルールを守る必要があり、時間とコストがかかる。その結果、製品承認に関わる厳格なルールが市場拡大を阻害する可能性があります。

マーケットリサーチレポートを購入する前に、どのような質問をすべきでしょうか？
- 抗ウイルス剤市場はどのように進化しているのか？
- 抗ウイルス剤市場の推進要因と抑制要因は何か？
- 各抗ウイルス剤サブマーケットセグメントは予測期間中にどのように成長し、2032年にどれくらいの収益を占めるようになるのか？
- 2022年から2032年にかけて、各抗ウイルス剤サブマーケットの市場シェアはどのように推移するのか？
- 2022年から2032年にかけて、市場全体の主なドライバーは何になるのでしょうか？
- 抗ウイルス剤の主要市場はマクロ経済のダイナミクスに概ね追随するのか、それとも個々の国別市場が他を凌駕するのか？
- 2032年までに各国市場のシェアはどのように変化し、どの地域が2032年に市場をリードするのか？
- 主要プレイヤーは誰か、また予測期間中の展望は？
- これらのリーディング企業の抗ウイルス剤プロジェクトは？
- 2022年から2032年の間に、業界はどのように進化していくのでしょうか？現在および今後10年間に実施される抗ウイルス剤プロジェクトにはどのような意味があるのか？
- 抗ウイルス剤市場の規模をさらに拡大するために、製品の商業化の必要性は高いか？
- 抗ウイルス剤市場はどこへ向かい、どのようにすれば市場の最前線に立つことができるのか？
- 新製品やサービスラインに対する最適な投資オプションは何か？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？

このことが現在、そして今後10年間の抗ウイルス剤市場にどのような影響を与えるかを知る必要があります。
- 286ページにわたる本レポートは、126の表と196のグラフを提供します。
- 本レポートでは、業界における主要な収益性の高い分野をハイライトしているため、今すぐその分野をターゲットにすることができます。
- 世界、地域、国別の売上高と成長率の詳細な分析が含まれています。
- 競合他社が成功した主なトレンド、変化、収益予測をハイライトしています。

本レポートは、抗ウイルス剤市場が今後10年間にどのように発展し、COVID-19の景気後退と回復の変動に沿うかを教えてくれます。この市場は、過去10年間のどの時点よりも今が重要なのです。

2032年までの予測やその他の分析により、商業的な展望が見えてくる
- 2032年までの収益予測に加え、直近の実績、成長率、市場シェアもご覧いただけます。
- ビジネスの展望や展開など、独自の分析もご覧いただけます。
- 定性的分析（市場力学、促進要因、機会、阻害要因、課題など）、コスト構造、抗ウイルス剤価格上昇の影響、最近の動向などをご覧いただけます。

本レポートでは、COVID-19が業界と貴社にどのような影響を与えるかについて、データ分析と貴重な洞察を掲載しています。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じています。

報告書の対象セグメント

薬物クラス
- DNAポリメラーゼ阻害剤
- 逆転写酵素阻害剤
- プロテアーゼ阻害剤
- ノイラミニダーゼ阻害剤
- その他

用途
- HIV/エイズ
- インフルエンザ
- 肝炎
- ヘルペス
- その他

エンドユーザー
- 病院
- クリニック
- その他

年齢層
- 成人
- 小児
- 老年

タイプ
- ブランド薬
- ジェネリック医薬品

世界市場全体とセグメントの収益予測に加え、4地域と主要20カ国市場の収益予測も掲載しています。

北米
- 米国
- カナダ

欧州
- ドイツ
- 英国
- フランス
- スペイン
- イタリア
- ロシア
- その他の欧州

アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- その他のアジア太平洋地域

ラテンアメリカ
- ブラジル
- メキシコ
- その他のラテンアメリカ地域

中東・アフリカ
- GCC
- 南アフリカ
- その他の中東・アフリカ地域

抗ウイルス剤市場の主要企業のプロファイルと2022年から2032年まで、これらの企業の事業のこのセグメントに焦点を当てます。

主要企業と市場成長の可能性
・ Abbott
・ AbbVie Inc.
・ AstraZeneca
・ Aurobindo Pharma
・ Bristol-Myers Squibb Company
・ Boehringer Ingelheim International GmbH
・ Cipla Inc.
・ Dr. Reddy’s Laboratories Ltd.
・ F. Hoffmann-La Roche Ltd
・ Gilead Sciences, Inc.
・ GlaxoSmithKline plc.
・ Johnson ＆ Johnson Private Limited
・ Merck KGaA
・ Novartis AG
・ Sun Pharmaceutical Industries Ltd.
・ Viatris Inc. (Mylan N. V.)

抗ウイルス剤市場の世界全体収益、金額ベースで2022年から2032年まで、市場は2022年に401億2000万米ドルを超えると、我々の仕事は計算されます。2032年まで力強い収益成長が予測される。本調査では、最も大きな可能性を秘めた企業を特定しました。彼らの能力、進歩、商業的展望を発見することで、一歩先を行くことができます。

抗ウイルス剤市場、2022年から2032年までのレポートはどのように役立つのでしょうか？
280ページを超えるレポートでは、要約すると以下のような知識を得ることができます。

- 抗ウイルス剤市場、2022年から2032年までの収益予測世界と地域レベルでの薬物クラス、アプリケーション、エンドユーザー、年齢層、タイプ別の各予測を掲載 - 業界の展望を発見し、投資と収益の最も有利な場所を見つけることができます。

- 5つの地域と20の主要国市場の2032年までの収益予測 - 北米、欧州、アジア太平洋、LAMEAの抗ウイルス剤市場、2022年から2032年までの市場予測をご覧ください。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなどの主要経済圏の市場も予測されています。

- 既存企業および市場参入を目指す企業の展望 - 抗ウイルス剤市場に関わる主要企業16社の企業プロファイルを含む、2022年から2032年までの展望。

定量的・定性的な分析と独自の予測をご覧いただけます。私たちのレポートだけが持つ情報を入手し、貴重なビジネスインテリジェンスを得ることができます。

他にはない情報
私たちの新しいレポートがあれば、知識の遅れを取り戻し、チャンスを逃す可能性が低くなります。私たちの研究が貴社の研究、分析、意思決定にどのように役立つかをご覧ください。Visiongainの研究は、抗ウイルス剤市場、2022年から2032年、市場をリードする企業のための商業分析を必要とするすべての人のためのものです。データ、トレンド、予測を見つけることができます。

ページTOPに戻る

1.レポートの概要
1.1 研究の目的
1.2 抗ウイルス剤市場の紹介
1.3 本レポートが提供するもの
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問には以下が含まれます。
1.6 本レポートは誰のためのものか？
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問（FAQ)
1.9 関連するVisiongainのレポート
1.10 Visiongainについて

2 エグゼクティブサマリー

3 市場の概要
3.1 主要な調査結果
3.2 マーケットダイナミクス
3.2.1 市場の推進要因
3.2.1.1 ウイルス性疾患の負担の増大
3.2.1.2 ブロックバスター治療薬の導入による市場成長の促進
3.2.2 市場阻害要因
3.2.2.1 製品承認に関する高い厳格性が市場成長を阻害する可能性が高い
3.2.2.2 医薬品開発のコスト高
3.2.3 市場機会
3.2.3.1 多数の製薬企業によるR&D活動への活発な投資
3.2.3.2 抗ウイルス剤への需要を生み出すウイルス性疾患の増加
3.3 COVID-19の影響度分析
3.4 ポーターのファイブフォース分析
3.4.1 供給者パワー
3.4.2 バイヤーパワー
3.4.3 競合他社の競争力
3.4.4 代替品による脅威
3.4.5 新規参入者の脅威
3.5 PEST分析
3.5.1 抗ウイルス剤市場に影響を与える政治的要因
3.5.2 抗ウイルス剤市場に影響を与える経済的要因
3.5.3 抗ウイルス剤市場に影響を与える社会的要因
3.5.4 抗ウイルス剤市場に影響を与える技術的要因

4 抗ウイルス剤市場分析：薬物クラス別
4.1 主要な調査結果
4.2 薬物クラスセグメント市場魅力度指数
4.3 抗ウイルス剤の薬物クラス別市場シェア、2022年＆2032年
4.4 DNAポリメラーゼ阻害剤
4.4.1 地域別市場規模、2022年～2032年（10億米ドル）
4.4.2 地域別市場シェア、2022年＆2032年(%)
4.5 逆転写酵素阻害剤
4.5.1 地域別市場規模、2022年〜2032年 (10億米ドル)
4.5.2 地域別市場シェア、2022年＆2032年(%)
4.6 プロテアーゼ阻害剤
4.6.1 地域別市場規模、2022年〜2032年 (10億米ドル)
4.6.2 地域別市場シェア、2022年＆2032年(%)
4.7 ノイラミニダーゼ阻害剤
4.7.1 地域別市場規模、2022年〜2032年 (10億米ドル)
4.7.2 地域別市場シェア、2022年＆2032年(%)
4.8 その他
4.8.1 地域別市場規模、2022年〜2032年 (10億米ドル)
4.8.2 地域別市場シェア、2022年＆2032年(%)

5 抗ウイルス剤市場分析：用途別
5.1 主な調査結果
5.2 用途別セグメント市場魅力度指数
5.3 抗ウイルス剤市場アプリケーション別シェア、2022年＆2032年
5.4 肝炎
5.4.1 地域別市場規模、2022年～2032年 (億米ドル)
5.4.2 地域別市場シェア（2022年＆2032年）(%)
5.5 HIV
5.5.1 地域別市場規模、2022年〜2032年 (10億米ドル)
5.5.2 地域別市場シェア、2022年＆2032年(%)
5.6 インフルエンザ
5.6.1 地域別市場規模、2022年〜2032年 (10億米ドル)
5.6.2 地域別市場シェア、2022年＆2032年(%)
5.7 ヘルペス
5.7.1 地域別市場規模、2022年～2032年 (10億米ドル)
5.7.2 地域別市場シェア、2022年＆2032年(%)
5.8 その他
5.8.1 地域別市場規模、2022年〜2032年 (10億米ドル)
5.8.2 地域別市場シェア、2022年＆2032年(%)

6 抗ウイルス剤市場分析：エンドユーザー別
6.1 主な調査結果
6.2 エンドユーザー・セグメント市場魅力度指数
6.3 抗ウイルス剤市場エンドユーザー別シェア、2022年＆2032年
6.4 病院
6.4.1 地域別市場規模、2022年～2032年（10億米ドル）
6.4.2 地域別市場シェア、2022年＆2032年(%)
6.5 クリニック
6.5.1 地域別市場規模、2022年～2032年 (10億米ドル)
6.5.2 地域別市場シェア、2022年＆2032年(%)
6.6 その他
6.6.1 地域別市場規模、2022年〜2032年 (10億米ドル)
6.6.2 地域別市場シェア、2022年＆2032年(%)

7 抗ウイルス剤市場分析：年齢層別
7.1 主な調査結果
7.2 年齢層別セグメント市場魅力度指数
7.3 抗ウイルス剤市場年齢層別シェア、2022年＆2032年
7.4 成人
7.4.1 地域別市場規模、2022年〜2032年 (億米ドル)
7.4.2 地域別市場シェア、2022年＆2032年(%)
7.5 老年
7.5.1 地域別市場規模、2022年～2032年 (10億米ドル)
7.5.2 地域別市場シェア、2022年＆2032年(%)
7.6 小児科
7.6.1 地域別市場規模、2022年～2032年 (10億米ドル)
7.6.2 地域別市場シェア、2022年＆2032年(%)

8 抗ウイルス剤市場分析：タイプ別
8.1 主な調査結果
8.2 タイプ別セグメント市場魅力度指数
8.3 抗ウイルス剤タイプ別市場シェア、2022年＆2032年
8.4 ブランド医薬品
8.4.1 地域別市場規模、2022年～2032年（10億米ドル）
8.4.2 地域別市場シェア、2022年＆2032年(%)
8.5 ジェネリック医薬品
8.5.1 地域別市場規模、2022年〜2032年 (10億米ドル)
8.5.2 地域別市場シェア、2022年＆2032年(%)

9 抗ウイルス剤市場分析：地域別
9.1 主な調査結果
9.2 地域別市場規模の推定と予測
9.3 COVID-19のインパクト分析

10 北米の抗ウイルス剤市場分析
10.1 主な調査結果
10.2 北米抗ウイルス剤市場の魅力度指数
10.3 北米の抗ウイルス剤国別市場 2022年、2027年＆2032年（10億米ドル）
10.4 北米の抗ウイルス剤国別市場規模予測・予想
10.5 北米の抗ウイルス剤市場の薬効別市場規模予測・予測
10.6 北米の抗ウイルス剤市場の用途別市場規模予測・予想
10.7 北米の抗ウイルス剤市場エンドユーザー別市場規模予測・予想
10.8 北米の抗ウイルス剤市場の年齢層別市場規模予測・予測
10.9 北米の抗ウイルス剤市場タイプ別市場規模予測・予測
10.10 米国の抗ウイルス剤市場分析
10.11 カナダの抗ウイルス剤市場の分析

11 欧州の抗ウイルス剤市場の分析
11.1 主な調査結果
11.2 欧州抗ウイルス剤市場魅力度指数
11.3 欧州抗ウイルス剤国別市場 2022年、2027年＆2032年（10億米ドル）
11.4 欧州抗ウイルス剤国別市場規模予測・予測
11.5 欧州抗ウイルス剤薬効別市場規模予測・予測（薬効別
11.6 欧州抗ウイルス剤市場の用途別市場規模予測・予測
11.7 欧州抗ウイルス剤市場のエンドユーザー別市場規模予測・予想
11.8 欧州の抗ウイルス剤の年齢層別市場規模予測・予測
11.9 欧州の抗ウイルス剤の市場規模予測・タイプ別予測
11.10 ドイツの抗ウイルス剤市場分析
11.11 イギリスの抗ウイルス剤市場の分析
11.12 フランスの抗ウイルス剤市場の分析
11.13 イタリアの抗ウイルス剤市場の分析
11.14 スペイン抗ウイルス剤市場の分析
11.15 ロシア抗ウイルス剤市場の分析
11.16 その他の欧州の抗ウイルス剤市場の分析

12 アジア太平洋地域の抗ウイルス剤市場分析
12.1 主な調査結果
12.2 アジア太平洋地域の抗ウイルス剤市場の魅力度指数
12.3 アジア太平洋地域の抗ウイルス剤国別市場、2022年、2027年＆2032年（10億米ドル）
12.4 アジア太平洋地域の抗ウイルス剤国別市場規模予測・予想
12.5 アジア太平洋地域の抗ウイルス剤市場の薬効別市場規模予測と予測
12.6 アジア太平洋地域の抗ウイルス剤市場の用途別市場規模予測・予測
12.7 アジア太平洋地域の抗ウイルス剤市場のエンドユーザー別市場規模予測・予想
12.8 アジア太平洋地域の抗ウイルス剤市場の年齢層別市場規模予測と予測
12.9 アジア太平洋地域の抗ウイルス剤市場タイプ別市場規模予測・予測
12.10 中国抗ウイルス剤市場の分析
12.11 日本の抗ウイルス剤市場の分析
12.12 インドの抗ウイルス剤市場の分析
12.13 オーストラリアの抗ウイルス剤市場の分析
12.14 韓国の抗ウイルス剤市場の分析
12.15 その他のアジア太平洋地域の抗ウイルス剤市場の分析

13 ラテンアメリカの抗ウイルス剤市場分析
13.1 主な調査結果
13.2 ラテンアメリカの抗ウイルス剤市場の魅力度指数
13.3 ラテンアメリカの抗ウイルス剤国別市場：2022年、2027年＆2032年（10億米ドル）
13.4 ラテンアメリカの国別抗ウイルス剤市場規模予測・予想
13.5 ラテンアメリカの抗ウイルス剤市場の薬効別市場規模予測・予測
13.6 ラテンアメリカの抗ウイルス剤市場の用途別市場規模予測・予想
13.7 ラテンアメリカの抗ウイルス剤市場のエンドユーザー別市場規模予測・予想
13.8 ラテンアメリカの抗ウイルス剤市場の年齢層別市場規模予測と予測
13.9 ラテンアメリカの抗ウイルス剤市場タイプ別市場規模予測・予測
13.10 ブラジルの抗ウイルス剤市場分析
13.11 メキシコの抗ウイルス剤市場の分析
13.12 その他のラテンアメリカの抗ウイルス剤市場の分析

14 中東・アフリカ抗ウイルス剤市場の分析
14.1 主な調査結果
14.2 中東・アフリカ抗ウイルス剤市場魅力度指数
14.3 中東・アフリカ抗ウイルス剤国別市場 2022年、2027年、2032年 (10億米ドル)
14.4 中東・アフリカ抗ウイルス剤国別市場規模予測・予測
14.5 中東・アフリカ抗ウイルス剤の薬効別市場規模予測・予測
14.6 中東・アフリカ抗ウイルス剤市場アプリケーション別市場規模予測・予想
14.7 中東・アフリカ抗ウイルス剤市場エンドユーザー別市場規模予測・予想
14.8 中東・アフリカ抗ウイルス剤の年齢層別市場規模予測・予想
14.9 中東・アフリカ地域の抗ウイルス剤のタイプ別市場規模予測・予想
14.10 GCCの抗ウイルス剤市場分析
14.11 南アフリカの抗ウイルス剤市場の分析
14.12 その他の中東・アフリカ地域の抗ウイルス剤市場の分析

15 主要企業のプロフィール
15.1 企業シェア分析
15.2 主要事業戦略分析
15.3 ジョンソン・エンド・ジョンソンサービス
15.3.1 企業スナップショット
15.3.2 会社概要
15.3.3 財務分析
15.3.3.1 純収益、2017年～2021年
15.3.3.2 地域別収益／マーケットシェア、2021年
15.3.3.3 セグメント別収益／マーケットシェア、2021年
15.3.4 製品ベンチマーク
15.3.5 戦略的な展望
15.4 メルクKGaA
15.4.1 企業スナップショット
15.4.2 会社概要
15.4.3 財務分析
15.4.3.1 純収益、2017-2021年
15.4.3.2 地域別収益／マーケットシェア、2021年
15.4.3.3 セグメント別収益／マーケットシェア、2021年
15.4.4 製品ベンチマーク
15.4.5 戦略的な展望
15.5 グラクソ・スミスクライン
15.5.1 企業スナップショット
15.5.2 会社概要
15.5.3 財務分析
15.5.3.1 純収益、2017-2021年
15.5.3.2 地域別収益／市場シェア、2021年
15.5.3.3 セグメント別収益／マーケットシェア、2021年
15.5.4 製品ベンチマーク
15.5.5 戦略的な展望
15.6 ノバルティスAG
15.6.1 企業スナップショット
15.6.2 会社概要
15.6.3 財務分析
15.6.3.1 純収益、2017-2021年
15.6.3.2 地域別収益／マーケットシェア、2021年
15.6.3.3 セグメント別収益／マーケットシェア、2021年
15.6.4 製品ベンチマーク
15.6.5 戦略的な展望
15.7 F. ホフマン・ラ・ロシュ社
15.7.1 企業スナップショット
15.7.2 会社概要
15.7.3 財務分析
15.7.3.1 純収益、2017-2021年
15.7.3.2 地域別収益／マーケットシェア、2021年
15.7.3.3 セグメント別収益／マーケットシェア、2021年
15.7.4 製品ベンチマーク
15.7.5 戦略的な展望
15.8 アストラゼネカ
15.8.1 企業スナップショット
15.8.2 会社概要
15.8.3 財務分析
15.8.3.1 純収益、2017-2021年
15.8.3.2 地域別売上高シェア、2021年
15.8.4 製品ベンチマーク
15.8.5 戦略的な展望
15.9 ブリストル・マイヤーズスクイブ社
15.9.1 企業スナップショット
15.9.2 会社概要
15.9.3 財務分析
15.9.3.1 純収益、2017-2021年
15.9.3.2 地域別売上高シェア、2021年
15.9.4 製品ベンチマーク
15.9.5 戦略的な展望
15.10 アッヴィー社
15.10.1 企業スナップショット
15.10.2 会社概要
15.10.3 財務分析
15.10.3.1 純収益、2017-2021年
15.10.3.2 製品収益シェア、2021年
15.10.3.3 地域別収益シェア、2021年
15.10.4 製品ベンチマーク
15.10.5 戦略的な展望
15.11 ギリアド・サイエンシズ社
15.11.1 企業スナップショット
15.11.2 会社概要
15.11.3 財務分析
15.11.3.1 純収益、2017-2021年
15.11.3.2 製品収益シェア、2021年
15.11.3.3 地域別収益シェア、2021年
15.11.4 製品ベンチマーク
15.11.5 戦略的な展望
15.12 ベーリンガーインゲルハイムインターナショナルGmbH
15.12.1 企業スナップショット
15.12.2 会社概要
15.12.3 財務分析
15.12.3.1 純収益、2017-2021年
15.12.3.2 製品収益シェア、2021年
15.12.3.3 地域別収益シェア、2021年
15.12.4 製品ベンチマーク
15.12.5 戦略的な展望
15.13 シプラ社
15.13.1 企業スナップショット
15.13.2 会社概要
15.13.3 財務分析
15.13.3.1 製品収益シェア、2021年
15.13.4 製品ベンチマーク
15.13.5 戦略的な展望
15.14 アボット
15.14.1 企業スナップショット
15.14.2 会社概要
15.14.3 財務分析
15.14.3.1 純収益、2017-2021年
15.14.3.2 製品収益シェア、2021年
15.14.3.3 地域別収益シェア、2021年
15.14.4 製品ベンチマーク
15.15 ビアトリス（マイランN.V.）
15.15.1 企業スナップショット
15.15.2 会社概要
15.15.3 財務分析
15.15.3.1 純収益、2017-2021年
15.15.3.2 地域別収益シェア、2021年
15.15.4 製品ベンチマーク
15.15.5 戦略的な展望
15.16 サン・ファーマシューティカル・インダストリーズ
15.16.1 企業スナップショット
15.16.2 会社概要
15.16.3 財務分析
15.16.3.1 純収益、2017-2021年
15.16.3.2 地域別売上高シェア、2021年
15.16.4 製品ベンチマーク
15.17 オーロビンド・ファーマ
15.17.1 企業スナップショット
15.17.2 会社概要
15.17.3 財務分析
15.17.3.1 純収益、2017-2021年
15.17.4 製品ベンチマーク
15.18 ドクター・レディーズ・ラボラトリーズ・リミテッド
15.18.1 企業スナップショット
15.18.2 会社概要
15.18.3 財務分析
15.18.3.1 純収益、2017-2021年
15.18.3.2 製品収益シェア、2021年
15.18.4 製品ベンチマーク
15.18.5 戦略的展望

16 結論と提言
16.1 ヴィジョンゲインからの結論
16.2 市場関係者への提言

表の一覧
Table 1 Antiviral Drugs Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Estimated Number of People Living with HIV, 2020−2021
Table 3 HIV-related Deaths, 2020−2021
Table 4 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “V” Shaped Recovery Scenario
Table 5 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “U” Shaped Recovery Scenario
Table 6 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “W” Shaped Recovery Scenario
Table 7 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “L” Shaped Recovery Scenario
Table 8 Commonly used DNA Polymerase Inhibitors
Table 9 DNA Polymerase Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 10 Commonly used Reverse Transcriptase Inhibitors
Table 11 Reverse Transcriptase Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 12 Protease Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 13 Commonly used Neuraminidase Inhibitor’s
Table 14 Neuraminidase Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 15 Other Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 16 Hepatitis Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 17 HIV Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 18 Influenza Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 19 Herpes Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 20 Others Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 21 Hospitals Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 22 Clinics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 23 Others Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 24 Adult Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 25 Geriatrics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 26 Pediatrics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 27 Branded Drugs Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 28 Generic Drugs Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 29 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%))
Table 30 North America Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 31 North America Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 32 North America Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 33 North America Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 34 North America Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 35 North America Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 36 U.S. Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 37 Canada Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 38 Europe Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 39 Europe Antiviral Drugs Market Forecast by drug class, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 40 Europe Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 41 Europe Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 42 Europe Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 43 Europe Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 44 Germany Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 45 U.K. Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 46 France Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 47 Italy Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 48 Spain Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 49 Russia Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 50 Rest of Europe Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 51 Asia Pacific Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 52 Asia Pacific Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 53 Asia Pacific Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 54 Asia Pacific Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 55 Asia Pacific Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 56 Asia Pacific Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 57 China Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 58 Japan Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 59 India Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 60 Australia Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 61 South Korea Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 62 Rest of Asia Pacific Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 63 Latin America Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 64 Latin America Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 65 Latin America Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 66 Latin America Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 67 Latin America Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 68 Latin America Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 69 Brazil Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 70 Mexico Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 71 Rest of Latin America Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 72 Middle East & Africa Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 73 Middle East & Africa Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 74 Middle East & Africa Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 75 Middle East & Africa Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 76 Middle East & Africa Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 77 Middle East & Africa Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 78 GCC Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 79 South Africa Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 80 Rest of Middle East & Africa Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 81 Antiviral Drugs Market Company Ranking for the Year 2021
F. Hoffmann-La Roche Ltd
Table 82 Johnson & Johnson Services, Inc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 83 Johnson & Johnson Services Inc. : Product Benchmarking
Table 84 Johnson & Johnson Services inc. : Strategic Outlook
Table 85 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 Merck KGaA : Product Benchmarking
Table 87 Merck KGaA : Strategic Outlook
Table 88 GlaxoSmithKline plc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 GlaxoSmithKline plc. : Product Benchmarking
Table 90 GlaxoSmithKline plc. : Strategic Outlook
Table 91 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 Novartis AG: Product Benchmarking
Table 93 Novartis AG: Strategic Outlook
Table 94 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 96 F. Hoffmann-La Roche Ltd : Strategic Outlook
Table 97 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 AstraZeneca: Product Benchmarking
Table 99 AstraZeneca : Strategic Outlook
Table 100 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Bristol-Myers Squibb Company: Product Benchmarking
Table 102 Bristol-Myers Squibb Company: Strategic Outlook
Table 103 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 AbbVie Inc.: Product Benchmarking
Table 105 AbbVie Inc.: Strategic Outlook
Table 106 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Gilead Sciences, Inc. Product Benchmarking
Table 108 Gilead Sciences Inc. Strategic Outlook
Table 109 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Boehringer Ingelheim International GmbH: Product Benchmarking
Table 111 Boehringer Ingelheim International GmbH; Strategic Outlook
Table 112 Cipla Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Cipla Inc.: Product Benchmarking
Table 114 Cipla Inc.: Strategic Outlook
Table 115 Abbott: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Abbott: Product Benchmarking
Table 117 Viatris: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Viatris: Product Benchmarking
Table 119 Viatris: Strategic Outlook
Table 120 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Sun Pharmaceutical Industries Ltd. : Product Benchmarking
Table 122 Aurobindo Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Aurobindo Pharma: Product Benchmarking
Table 124 Dr. Reddy’s Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 Dr. Reddy’s Laboratories ltd. : Product Benchmarking
Table 126 Dr. Reddy’s Laboratories Ltd. : Strategic Outlook

図の一覧
Figure 1 Antiviral Drugs Market Segmentation
Figure 2 Antiviral Drugs Market Forecast by Region: Market Attractiveness Index
Figure 3 Antiviral Drugs Market by Drug Class: Market Attractiveness Index
Figure 4 Antiviral Drugs Market by Application: Market Attractiveness Index
Figure 5 Antiviral Drugs Market by End-users: Market Attractiveness Index
Figure 6 Antiviral Drugs Market by Age Group: Market Attractiveness Index
Figure 7 Antiviral Drugs Market by Type: Market Attractiveness Index
Figure 8 Antiviral Drugs Market: Market Dynamics
Figure 9 COVID Impact Analysis: Antiviral Drugs Market Recovery Scenarios
Figure 10 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 11 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 12 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 13 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 14 Antiviral Drugs Market: Porter’s Five Forces Analysis
Figure 15 Antiviral Drugs Market: PEST Analysis
Figure 16 Antiviral Drugs Market Forecast by Drug Class Segment: Market Attractiveness Index
Figure 17 Antiviral Drugs Market Share Forecast by Drug Class, 2022, 2032 (%)
Figure 18 DNA Polymerase Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 19 DNA Polymerase Inhibitors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 20 Reverse Transcriptase Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 21 Reverse Transcriptase Inhibitors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 22 Protease Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 23 Protease Inhibitors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 24 Neuraminidase Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 25 Neuraminidase Inhibitors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 26 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 27 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 28 Antiviral Drugs Market Forecast by Application Segment: Market Attractiveness Index
Figure 29 Antiviral Drugs Market Share Forecast by Application, 2022, 2032 (%)
Figure 30 Hepatitis Market Forecast by Region, 2022-2032 (US$ billion)
Figure 31 Hepatitis Market Share Forecast by Region, 2022 & 2032 (%)
Figure 32 HIV Market Forecast by Region, 2022-2032 (US$ billion)
Figure 33 HIV Market Share Forecast by Region, 2022 & 2032 (%)
Figure 34 Influenza Market Forecast by Region, 2022-2032 (US$ billion)
Figure 35 Influenza Market Share Forecast by Region, 2022 & 2032 (%)
Figure 36 Herpes Market Forecast by Region, 2022-2032 (US$ billion)
Figure 37 Herpes Market Share Forecast by Region, 2022 & 2032 (%)
Figure 38 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 39 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 40 Antiviral Drugs Market Forecast by End-users Segment: Market Attractiveness Index
Figure 41 Antiviral Drugs Market Share Forecast by End-users, 2022, 2032 (%)
Figure 42 Hospitals Market Forecast by Region, 2022-2032 (US$ billion)
Figure 43 Hospitals Market Share Forecast by Region, 2022 & 2032 (%)
Figure 44 Clinics Market Forecast by Region, 2022-2032 (US$ billion)
Figure 45 Clinics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 46 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 47 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 48 Antiviral Drugs Market Forecast by Age Group Segment: Market Attractiveness Index
Figure 49 Antiviral Drugs Market Share Forecast by Age Group, 2022, 2032 (%)
Figure 50 Adult Market Forecast by Region, 2022-2032 (US$ billion)
Figure 51 Adult Market Share Forecast by Region, 2022 & 2032 (%)
Figure 52 Geriatrics Market Forecast by Region, 2022-2032 (US$ billion)
Figure 53 Geriatrics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 54 Pediatrics Market Forecast by Region, 2022-2032 (US$ billion)
Figure 55 Pediatrics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 56 Antiviral Drugs Market Forecast by Type Segment: Market Attractiveness Index
Figure 57 Antiviral Drugs Market Share Forecast by Type, 2022, 2032 (%)
Figure 58 Branded Drugs Market Forecast by Region, 2022-2032 (US$ billion)
Figure 59 Branded Drugs Market Share Forecast by Region, 2022 & 2032 (%)
Figure 60 Generic Drugs Market Forecast by Region, 2022-2032 (US$ billion)
Figure 61 Generic Drugs Market Share Forecast by Region, 2022 & 2032 (%)
Figure 62 Antiviral Drugs Market Forecast by Region 2022 v.s. 2032 (Revenue, CAGR %)
Figure 63 Antiviral Drugs Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 64 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%))
Figure 65 North America Antiviral Drugs Market Attractiveness Index
Figure 66 North America Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 67 North America Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 68 North America Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 69 North America Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 70 North America Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 71 North America Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 72 North America Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 73 North America Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 74 North America Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 75 North America Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 76 North America Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 77 North America Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 78 North America Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 79 U.S. Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 80 Canada Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 81 Europe Antiviral Drugs Market Attractiveness Index
Figure 82 Europe Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 83 Europe Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 84 Europe Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 85 Europe Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 86 Europe Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 87 Europe Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 88 Europe Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 89 Europe Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 90 Europe Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 91 Europe Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 92 Europe Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 93 Europe Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 94 Europe Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 95 Germany Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 96 U.K. Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 97 France Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 98 Italy Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 99 Spain Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 100 Russia Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 101 Rest of Europe Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 102 Asia Pacific Antiviral Drugs Market Attractiveness Index
Figure 103 Asia Pacific Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 104 Asia Pacific Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 105 Asia Pacific Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 106 Asia Pacific Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 107 Asia Pacific Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 108 Asia Pacific Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 109 Asia Pacific Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 110 Asia Pacific Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 111 Asia Pacific Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 112 Asia Pacific Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 113 Asia Pacific Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 114 Asia Pacific Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 115 Asia Pacific Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 116 China Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 117 Japan Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 118 India Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 119 Australia Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 120 South Korea Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 121 Rest of Asia Pacific Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 122 Latin America Antiviral Drugs Market Attractiveness Index
Figure 123 Latin America Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 124 Latin America Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 125 Latin America Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 126 Latin America Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 127 Latin America Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 128 Latin America Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 129 Latin America Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 130 Latin America Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 131 Latin America Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 132 Latin America Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 133 Latin America Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 134 Latin America Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 135 Latin America Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 136 Brazil Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 137 Mexico Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 138 Rest of Latin America Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 139 Middle East & Africa Antiviral Drugs Market Attractiveness Index
Figure 140 Middle East & Africa Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 141 Middle East & Africa Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 142 Middle East & Africa Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 143 Middle East & Africa Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 144 Middle East & Africa Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 145 Middle East & Africa Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 146 Middle East & Africa Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 147 Middle East & Africa Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 148 Middle East & Africa Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 149 Middle East & Africa Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 150 Middle East & Africa Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 151 Middle East & Africa Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 152 Middle East & Africa Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 153 GCC Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 154 South Africa Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 155 Rest of Middle East & Africa Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 157 Johnson & Johnson Services Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 158 Johnson & Johnson Services Inc. : Regional Revenue Shares, 2021
Figure 159 Johnson & Johnson Services Inc. : Segmental Revenue Shares, 2021
Figure 160 Merck KGaA : Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 161 Merck KGaA : Regional Revenue Shares, 2021
Figure 162 Merck KGaA : Segmental Revenue Shares, 2021
Figure 163 GlaxoSmithKline plc. : Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 164 GlaxoSmithKline plc. : Regional Revenue Shares, 2021
Figure 165 GlaxoSmithKline plc. : Segmental Revenue Shares, 2021
Figure 166 Novartis AG: Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 167 Novartis AG: Regional Revenue Shares, 2021
Figure 168 Novartis AG: Segmental Revenue Shares, 2021
Figure 169 F. Hoffmann-La Roche Ltd : Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 170 F. Hoffmann-La Roche Ltd : Regional Revenue Shares, 2021
Figure 171 F. Hoffmann-La Roche Ltd : Segmental Revenue Shares, 2021
Figure 172 AstraZeneca: Net Revenue, 2017-2021 (US $ million, AGR %)
Figure 173 AstraZeneca: Regional Revenue Shares, 2021
Figure 174 Bristol-Myers Squibb Company: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 175 Bristol-Myers Squibb Company: Regional Revenue Shares, 2021
Figure 176 AbbVie Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 177 AbbVie Inc.: Product Revenue Shares, 2021
Figure 178 AbbVie Inc.: Regional Revenue Shares, 2021
Figure 179 Gilead Sciences, Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 180 Gilead Sciences, Inc.: Product Revenue Shares, 2021
Figure 181 Gilead Sciences, Inc.: Regional Revenue Shares, 2021
Figure 182 Boehringer Ingelheim International GmbH : Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 183 Boehringer Ingelheim International GmbH Product Revenue Shares, 2021
Figure 184 Boehringer Ingelheim International GmbH: Regional Revenue Shares, 2021
Figure 185 Cipla: Product Revenue Shares, 2021
Figure 186 Abbott: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 187 Abbott: Product Revenue Shares, 2021
Figure 188 Abbott: Regional Revenue Shares, 2021
Figure 189 Viatris: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 190 Viatris: Regional Revenue Shares, 2021
Figure 191 Sun Pharmaceutical Industries Ltd. : Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 192 Sun Pharmaceutical Industries Ltd.: Regional Revenue Shares, 2021
Figure 193 Aurobindo Pharma: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 194 Dr. Reddy’s Laboratories Ltd. : Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 195 Dr. Reddy’s Laboratories Ltd. : Product Revenue Shares, 2021
Figure 196 Antiviral Drugs Market Share Forecast by Region, 2022, 2026, 2032 (%)

ページTOPに戻る

Table of Contents

Summary

Report Details

The Antiviral Drugs Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Introduction of Blockbuster Drugs to Boost Market Growth
Antiviral medicines are being actively researched and developed by a number of major pharmaceutical companies. Antiretroviral therapy has evolved dramatically since the emergence of blockbuster medications like Gilead Science’s Biktarvy and GlaxoSmithKline’s Triumeq. The antiviral market revenue is expected to grow between 2022 and 2032 because to rising consumption of such blockbuster medicines and increased distribution by producers.

The demand for antiviral medications has increased due to the COVID-19 pandemic. Due to a sharp increase in COVID-19 cases and healthcare facilities focusing their efforts primarily on treating COVID-19 patients, the market has grown. Additionally, a number of pharmaceutical firms were focusing their efforts on the development of novel drugs in order to offer patients better patient outcomes and more effective treatments. These businesses worked together to meet product demand throughout the time period.

For instance, Johnson & Johnson announced in March 2022 that a historic agreement between Janssen Pharmaceuticals, Inc. and the South African manufacturer Aspen SA Operations (Pty) Ltd had been completed. With the goal of increasing COVID-19 immunization rates across the continent, this will enable the first COVID-19 vaccine to be developed and distributed by an African company for use by people who reside in Africa. Therefore, active cooperation and deliberate attempts by market participants to improve their antiviral drug production capacity to serve a broader patient population have fuelled the market share for all antiviral treatments.

High Stringency Related to Product Approvals Likely to Hamper Market Growth
Pharmaceutical product manufacturing necessitates a high level of regulatory compliance in terms of consumer safety. However, because of the compliance requirements, this raises R spending. Antiviral drug registration necessitates formulation documentation. Comparative testing is very significant for antiviral medicines. The documentation, testing, and approval requirements differ by nation. Economic, legal, and cultural circumstances in each country are some of the elements that influence the diverse approaches.

Antiviral medications must have demonstrated clinical efficacy when given to patients who meet the products criteria. The U.S. Food and Drug Administration (FDA) must receive an Abbreviated New Drug Application (ANDA). In the US, the FDA is in control, but the EMA is in charge in Europe. The bioequivalence of medications is demonstrated for oral drugs based on drug concentration in the body. Each nation has its own regulatory bodies that certify medicines for sale in domestic markets. Pharmaceutical business must work hard to acquire approval in many countries and adhere to various rules, which is a time-consuming and costly process. As a result strict rules associated with product approval may stifle market expansion.

What Questions Should You Ask before Buying a Market Research Report?
• How is the antiviral drugs market evolving?
• What is driving and restraining the antiviral drugs market?
• How will each antiviral drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each antiviral drugs submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading antiviral drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the antiviral drugs projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of antiviral drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the antiviral drugs market?
• Where is the antiviral drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the antiviral drugs market today, and over the next 10 years:
• Our 286-page report provides 126 tables and 196 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the antiviral drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising antiviral drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Drug Class
• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Others

Application
• HIV/AIDS
• Influenza
• Hepatitis
• Herpes
• Other

End User
• Hospitals
• Clinics
• Others

Age Group
• Adult
• Pediatric
• Geriatric

Type
• Branded Drugs
• Generic Drugs

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa
• GCC
• South Africa
• Rest of Middle East & Africa

The report also includes profiles and for some of the leading companies in the Antiviral Drugs Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Abbott
• AbbVie Inc.
• AstraZeneca
• Aurobindo Pharma
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Cipla Inc.
• Dr. Reddy’s Laboratories Ltd.
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline plc.
• Johnson & Johnson Private Limited
• Merck KGaA
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc. (Mylan N. V.)

Overall world revenue for Antiviral Drugs Market, 2022 to 2032 in terms of value the market will surpass US$40.12 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Antiviral Drugs Market, 2022 to 2032 report help you?
In summary, our 280+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Antiviral Drugs Market, 2022 to 2032 Market, with forecasts for drug class, application, end user, age group, and type each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for five regional and 20 key national markets – See forecasts for the Antiviral Drugs Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 16 of the major companies involved in the Antiviral Drugs Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Antiviral Drugs Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Antiviral Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Growing Viral Diseases Burden
3.2.1.2 Introduction of Blockbuster Therapeutics to Boost Market Growth
3.2.2 Market Restraining Factors
3.2.2.1 High Stringency Related to Product Approvals Likely to Hamper Market Growth
3.2.2.2 High Cost of Drug Development
3.2.3 Market Opportunities
3.2.3.1 Robust Investment in R&D Activities by Numerous Pharmaceutical Organizations
3.2.3.2 Growing Viral Disease Creating Demand for Antiviral Drugs
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political Factors Impacting Antiviral Drug Market
3.5.2 Economic Factors Impacting Antiviral Drug Market
3.5.3 Social Factors Impacting Antiviral Drug Market
3.5.4 Technological Factors Impacting Antiviral Drug Market

4 Antiviral Drugs Market Analysis by Drug Class
4.1 Key Findings
4.2 Drug Class Segment: Market Attractiveness Index
4.3 Antiviral Drugs Market Share by Drug Class, 2022 & 2032
4.4 DNA Polymerase Inhibitors
4.4.1 Market Size by Region, 2022-2032 (US$ bn)
4.4.2 Market Share by Region, 2022 & 2032 (%)
4.5 Reverse Transcriptase Inhibitors
4.5.1 Market Size by Region, 2022-2032 (US$ bn)
4.5.2 Market Share by Region, 2022 & 2032 (%)
4.6 Protease Inhibitors
4.6.1 Market Size by Region, 2022-2032 (US$ bn)
4.6.2 Market Share by Region, 2022 & 2032 (%)
4.7 Neuraminidase Inhibitors
4.7.1 Market Size by Region, 2022-2032 (US$ bn)
4.7.2 Market Share by Region, 2022 & 2032 (%)
4.8 Others
4.8.1 Market Size by Region, 2022-2032 (US$ bn)
4.8.2 Market Share by Region, 2022 & 2032 (%)

5 Antiviral Drugs Market Analysis by Application
5.1 Key Findings
5.2 Application Segment: Market Attractiveness Index
5.3 Antiviral Drugs Market Share by Application, 2022 & 2032
5.4 Hepatitis
5.4.1 Market Size by Region, 2022-2032 (US$ bn)
5.4.2 Market Share by Region, 2022 & 2032 (%)
5.5 HIV
5.5.1 Market Size by Region, 2022-2032 (US$ bn)
5.5.2 Market Share by Region, 2022 & 2032 (%)
5.6 Influenza
5.6.1 Market Size by Region, 2022-2032 (US$ bn)
5.6.2 Market Share by Region, 2022 & 2032 (%)
5.7 Herpes
5.7.1 Market Size by Region, 2022-2032 (US$ bn)
5.7.2 Market Share by Region, 2022 & 2032 (%)
5.8 Others
5.8.1 Market Size by Region, 2022-2032 (US$ bn)
5.8.2 Market Share by Region, 2022 & 2032 (%)

6 Antiviral Drugs Market Analysis by End User
6.1 Key Findings
6.2 End-users Segment: Market Attractiveness Index
6.3 Antiviral Drugs Market Share by End-users, 2022 & 2032
6.4 Hospitals
6.4.1 Market Size by Region, 2022-2032 (US$ bn)
6.4.2 Market Share by Region, 2022 & 2032 (%)
6.5 Clinics
6.5.1 Market Size by Region, 2022-2032 (US$ bn)
6.5.2 Market Share by Region, 2022 & 2032 (%)
6.6 Others
6.6.1 Market Size by Region, 2022-2032 (US$ bn)
6.6.2 Market Share by Region, 2022 & 2032 (%)

7 Antiviral Drugs Market Analysis by Age Group
7.1 Key Findings
7.2 Age Group Segment: Market Attractiveness Index
7.3 Antiviral Drugs Market Share by Age Group, 2022 & 2032
7.4 Adults
7.4.1 Market Size by Region, 2022-2032 (US$ bn)
7.4.2 Market Share by Region, 2022 & 2032 (%)
7.5 Geriatrics
7.5.1 Market Size by Region, 2022-2032 (US$ bn)
7.5.2 Market Share by Region, 2022 & 2032 (%)
7.6 Pediatrics
7.6.1 Market Size by Region, 2022-2032 (US$ bn)
7.6.2 Market Share by Region, 2022 & 2032 (%)

8 Antiviral Drugs Market Analysis by Type
8.1 Key Findings
8.2 Type Segment: Market Attractiveness Index
8.3 Antiviral Drugs Market Share by Type, 2022 & 2032
8.4 Branded Drugs
8.4.1 Market Size by Region, 2022-2032 (US$ bn)
8.4.2 Market Share by Region, 2022 & 2032 (%)
8.5 Generic Drugs
8.5.1 Market Size by Region, 2022-2032 (US$ bn)
8.5.2 Market Share by Region, 2022 & 2032 (%)

9 Antiviral Drugs Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast
9.3 COVID-19 Impact Analysis

10 North America Antiviral Drugs Market Analysis
10.1 Key Findings
10.2 North America Antiviral Drugs Market Attractiveness Index
10.3 North America Antiviral Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
10.4 North America Antiviral Drugs Market Size Estimation and Forecast by Country
10.5 North America Antiviral Drugs Market Size Estimation and Forecast by Drug Class
10.6 North America Antiviral Drugs Market Size Estimation and Forecast by Application
10.7 North America Antiviral Drugs Market Size Estimation and Forecast by End-users
10.8 North America Antiviral Drugs Market Size Estimation and Forecast by Age Group
10.9 North America Antiviral Drugs Market Size Estimation and Forecast by Type
10.10 U.S. Antiviral Drugs Market Analysis
10.11 Canada Antiviral Drugs Market Analysis

11 Europe Antiviral Drugs Market Analysis
11.1 Key Findings
11.2 Europe Antiviral Drugs Market Attractiveness Index
11.3 Europe Antiviral Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
11.4 Europe Antiviral Drugs Market Size Estimation and Forecast by Country
11.5 Europe Antiviral Drugs Market Size Estimation and Forecast by Drug Class
11.6 Europe Antiviral Drugs Market Size Estimation and Forecast by Application
11.7 Europe Antiviral Drugs Market Size Estimation and Forecast by End-users
11.8 Europe Antiviral Drugs Market Size Estimation and Forecast by Age Group
11.9 Europe Antiviral Drugs Market Size Estimation and Forecast by Type
11.10 Germany Antiviral Drugs Market Analysis
11.11 U.K. Antiviral Drugs Market Analysis
11.12 France Antiviral Drugs Market Analysis
11.13 Italy Antiviral Drugs Market Analysis
11.14 Spain Antiviral Drugs Market Analysis
11.15 Russia Antiviral Drugs Market Analysis
11.16 Rest of Europe Antiviral Drugs Market Analysis

12 Asia Pacific Antiviral Drugs Market Analysis
12.1 Key Findings
12.2 Asia Pacific Antiviral Drugs Market Attractiveness Index
12.3 Asia Pacific Antiviral Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
12.4 Asia Pacific Antiviral Drugs Market Size Estimation and Forecast by Country
12.5 Asia Pacific Antiviral Drugs Market Size Estimation and Forecast by Drug Class
12.6 Asia Pacific Antiviral Drugs Market Size Estimation and Forecast by Application
12.7 Asia Pacific Antiviral Drugs Market Size Estimation and Forecast by End-users
12.8 Asia Pacific Antiviral Drugs Market Size Estimation and Forecast by Age Group
12.9 Asia Pacific Antiviral Drugs Market Size Estimation and Forecast by Type
12.10 China Antiviral Drugs Market Analysis
12.11 Japan Antiviral Drugs Market Analysis
12.12 India Antiviral Drugs Market Analysis
12.13 Australia Antiviral Drugs Market Analysis
12.14 South Korea Antiviral Drugs Market Analysis
12.15 Rest of Asia Pacific Antiviral Drugs Market Analysis

13 Latin America Antiviral Drugs Market Analysis
13.1 Key Findings
13.2 Latin America Antiviral Drugs Market Attractiveness Index
13.3 Latin America Antiviral Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
13.4 Latin America Antiviral Drugs Market Size Estimation and Forecast by Country
13.5 Latin America Antiviral Drugs Market Size Estimation and Forecast by Drug Class
13.6 Latin America Antiviral Drugs Market Size Estimation and Forecast by Application
13.7 Latin America Antiviral Drugs Market Size Estimation and Forecast by End-users
13.8 Latin America Antiviral Drugs Market Size Estimation and Forecast by Age Group
13.9 Latin America Antiviral Drugs Market Size Estimation and Forecast by Type
13.10 Brazil Antiviral Drugs Market Analysis
13.11 Mexico Antiviral Drugs Market Analysis
13.12 Rest of Latin America Antiviral Drugs Market Analysis

14 Middle East & Africa Antiviral Drugs Market Analysis
14.1 Key Findings
14.2 Middle East & Africa Antiviral Drugs Market Attractiveness Index
14.3 Middle East & Africa Antiviral Drugs Market by Country, 2022, 2027 & 2032 (US$ bn)
14.4 Middle East & Africa Antiviral Drugs Market Size Estimation and Forecast by Country
14.5 Middle East & Africa Antiviral Drugs Market Size Estimation and Forecast by Drug Class
14.6 Middle East & Africa Antiviral Drugs Market Size Estimation and Forecast by Application
14.7 Middle East & Africa Antiviral Drugs Market Size Estimation and Forecast by End-users
14.8 Middle East & Africa Antiviral Drugs Market Size Estimation and Forecast by Age Group
14.9 Middle East & Africa Antiviral Drugs Market Size Estimation and Forecast by Type
14.10 GCC Antiviral Drugs Market Analysis
14.11 South Africa Antiviral Drugs Market Analysis
14.12 Rest of Middle East & Africa Antiviral Drugs Market Analysis

15 Company Profiles
15.1 Company Share Analysis
15.2 Key Business Strategy Analysis
15.3 Johnson & Johnson Services, Inc.
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2017-2021
15.3.3.2 Regional Revenue/Market Shares, 2021
15.3.3.3 Segmental Revenue/Market Shares, 2021
15.3.4 Product Benchmarking
15.3.5 Strategic Outlook
15.4 Merck KGaA
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2017-2021
15.4.3.2 Regional Revenue/Market Shares, 2021
15.4.3.3 Segmental Revenue/Market Shares, 2021
15.4.4 Product Benchmarking
15.4.5 Strategic Outlook
15.5 GlaxoSmithKline plc.
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2017-2021
15.5.3.2 Regional Revenue/Market Shares, 2021
15.5.3.3 Segmental Revenue/Market Shares, 2021
15.5.4 Product Benchmarking
15.5.5 Strategic Outlook
15.6 Novartis AG
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2017-2021
15.6.3.2 Regional Revenue/Market Shares, 2021
15.6.3.3 Segmental Revenue/Market Shares, 2021
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.7 F. Hoffmann-La Roche Ltd
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2017-2021
15.7.3.2 Regional Revenue/Market Shares, 2021
15.7.3.3 Segmental Revenue/Market Shares, 2021
15.7.4 Product Benchmarking
15.7.5 Strategic Outlook
15.8 AstraZeneca
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2017-2021
15.8.3.2 Regional Revenue Shares, 2021
15.8.4 Product Benchmarking
15.8.5 Strategic Outlook
15.9 Bristol-Myers Squibb Company
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2017-2021
15.9.3.2 Regional Revenue Shares, 2021
15.9.4 Product Benchmarking
15.9.5 Strategic Outlook
15.10 AbbVie Inc.
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2017-2021
15.10.3.2 Product Revenue Shares, 2021
15.10.3.3 Regional Revenue Shares, 2021
15.10.4 Product Benchmarking
15.10.5 Strategic Outlook
15.11 Gilead Sciences, Inc.
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Financial Analysis
15.11.3.1 Net Revenue, 2017-2021
15.11.3.2 Product Revenue Shares, 2021
15.11.3.3 Regional Revenue Shares, 2021
15.11.4 Product Benchmarking
15.11.5 Strategic Outlook
15.12 Boehringer Ingelheim International GmbH
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Financial Analysis
15.12.3.1 Net Revenue, 2017-2021
15.12.3.2 Product Revenue Shares, 2021
15.12.3.3 Regional Revenue Shares, 2021
15.12.4 Product Benchmarking
15.12.5 Strategic Outlook
15.13 Cipla Inc.
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Product Revenue Shares, 2021
15.13.4 Product Benchmarking
15.13.5 Strategic Outlook
15.14 Abbott
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Financial Analysis
15.14.3.1 Net Revenue, 2017-2021
15.14.3.2 Product Revenue Shares, 2021
15.14.3.3 Regional Revenue Shares, 2021
15.14.4 Product Benchmarking
15.15 Viatris (Mylan N. V.)
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Financial Analysis
15.15.3.1 Net Revenue, 2017-2021
15.15.3.2 Regional Revenue Shares, 2021
15.15.4 Product Benchmarking
15.15.5 Strategic Outlook
15.16 Sun Pharmaceutical Industries Ltd.
15.16.1 Company Snapshot
15.16.2 Company Overview
15.16.3 Financial Analysis
15.16.3.1 Net Revenue, 2017-2021
15.16.3.2 Regional Revenue Shares, 2021
15.16.4 Product Benchmarking
15.17 Aurobindo Pharma
15.17.1 Company Snapshot
15.17.2 Company Overview
15.17.3 Financial Analysis
15.17.3.1 Net Revenue, 2017-2021
15.17.4 Product Benchmarking
15.18 Dr. Reddy’s Laboratories Ltd.
15.18.1 Company Snapshot
15.18.2 Company Overview
15.18.3 Financial Analysis
15.18.3.1 Net Revenue, 2017-2021
15.18.3.2 Product Revenue Shares, 2021
15.18.4 Product Benchmarking
15.18.5 Strategic Outlook

16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players

List of Tables
Table 1 Antiviral Drugs Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Estimated Number of People Living with HIV, 2020−2021
Table 3 HIV-related Deaths, 2020−2021
Table 4 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “V” Shaped Recovery Scenario
Table 5 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “U” Shaped Recovery Scenario
Table 6 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “W” Shaped Recovery Scenario
Table 7 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “L” Shaped Recovery Scenario
Table 8 Commonly used DNA Polymerase Inhibitors
Table 9 DNA Polymerase Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 10 Commonly used Reverse Transcriptase Inhibitors
Table 11 Reverse Transcriptase Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 12 Protease Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 13 Commonly used Neuraminidase Inhibitor’s
Table 14 Neuraminidase Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 15 Other Inhibitors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 16 Hepatitis Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 17 HIV Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 18 Influenza Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 19 Herpes Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 20 Others Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 21 Hospitals Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 22 Clinics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 23 Others Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 24 Adult Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 25 Geriatrics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 26 Pediatrics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 27 Branded Drugs Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 28 Generic Drugs Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 29 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%))
Table 30 North America Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 31 North America Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 32 North America Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 33 North America Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 34 North America Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 35 North America Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 36 U.S. Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 37 Canada Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 38 Europe Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 39 Europe Antiviral Drugs Market Forecast by drug class, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 40 Europe Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 41 Europe Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 42 Europe Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 43 Europe Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 44 Germany Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 45 U.K. Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 46 France Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 47 Italy Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 48 Spain Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 49 Russia Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 50 Rest of Europe Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 51 Asia Pacific Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 52 Asia Pacific Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 53 Asia Pacific Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 54 Asia Pacific Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 55 Asia Pacific Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 56 Asia Pacific Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 57 China Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 58 Japan Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 59 India Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 60 Australia Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 61 South Korea Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 62 Rest of Asia Pacific Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 63 Latin America Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 64 Latin America Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 65 Latin America Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 66 Latin America Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 67 Latin America Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 68 Latin America Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 69 Brazil Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 70 Mexico Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 71 Rest of Latin America Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 72 Middle East & Africa Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 73 Middle East & Africa Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 74 Middle East & Africa Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 75 Middle East & Africa Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 76 Middle East & Africa Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 77 Middle East & Africa Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 78 GCC Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 79 South Africa Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR %)
Table 80 Rest of Middle East & Africa Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR%, CAGR%)
Table 81 Antiviral Drugs Market Company Ranking for the Year 2021
F. Hoffmann-La Roche Ltd
Table 82 Johnson & Johnson Services, Inc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 83 Johnson & Johnson Services Inc. : Product Benchmarking
Table 84 Johnson & Johnson Services inc. : Strategic Outlook
Table 85 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 Merck KGaA : Product Benchmarking
Table 87 Merck KGaA : Strategic Outlook
Table 88 GlaxoSmithKline plc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 GlaxoSmithKline plc. : Product Benchmarking
Table 90 GlaxoSmithKline plc. : Strategic Outlook
Table 91 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 Novartis AG: Product Benchmarking
Table 93 Novartis AG: Strategic Outlook
Table 94 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 96 F. Hoffmann-La Roche Ltd : Strategic Outlook
Table 97 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 AstraZeneca: Product Benchmarking
Table 99 AstraZeneca : Strategic Outlook
Table 100 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Bristol-Myers Squibb Company: Product Benchmarking
Table 102 Bristol-Myers Squibb Company: Strategic Outlook
Table 103 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 AbbVie Inc.: Product Benchmarking
Table 105 AbbVie Inc.: Strategic Outlook
Table 106 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Gilead Sciences, Inc. Product Benchmarking
Table 108 Gilead Sciences Inc. Strategic Outlook
Table 109 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Boehringer Ingelheim International GmbH: Product Benchmarking
Table 111 Boehringer Ingelheim International GmbH; Strategic Outlook
Table 112 Cipla Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Cipla Inc.: Product Benchmarking
Table 114 Cipla Inc.: Strategic Outlook
Table 115 Abbott: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Abbott: Product Benchmarking
Table 117 Viatris: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Viatris: Product Benchmarking
Table 119 Viatris: Strategic Outlook
Table 120 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Sun Pharmaceutical Industries Ltd. : Product Benchmarking
Table 122 Aurobindo Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Aurobindo Pharma: Product Benchmarking
Table 124 Dr. Reddy’s Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 Dr. Reddy’s Laboratories ltd. : Product Benchmarking
Table 126 Dr. Reddy’s Laboratories Ltd. : Strategic Outlook

List of Figures
Figure 1 Antiviral Drugs Market Segmentation
Figure 2 Antiviral Drugs Market Forecast by Region: Market Attractiveness Index
Figure 3 Antiviral Drugs Market by Drug Class: Market Attractiveness Index
Figure 4 Antiviral Drugs Market by Application: Market Attractiveness Index
Figure 5 Antiviral Drugs Market by End-users: Market Attractiveness Index
Figure 6 Antiviral Drugs Market by Age Group: Market Attractiveness Index
Figure 7 Antiviral Drugs Market by Type: Market Attractiveness Index
Figure 8 Antiviral Drugs Market: Market Dynamics
Figure 9 COVID Impact Analysis: Antiviral Drugs Market Recovery Scenarios
Figure 10 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 11 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 12 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 13 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 14 Antiviral Drugs Market: Porter’s Five Forces Analysis
Figure 15 Antiviral Drugs Market: PEST Analysis
Figure 16 Antiviral Drugs Market Forecast by Drug Class Segment: Market Attractiveness Index
Figure 17 Antiviral Drugs Market Share Forecast by Drug Class, 2022, 2032 (%)
Figure 18 DNA Polymerase Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 19 DNA Polymerase Inhibitors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 20 Reverse Transcriptase Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 21 Reverse Transcriptase Inhibitors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 22 Protease Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 23 Protease Inhibitors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 24 Neuraminidase Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 25 Neuraminidase Inhibitors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 26 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 27 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 28 Antiviral Drugs Market Forecast by Application Segment: Market Attractiveness Index
Figure 29 Antiviral Drugs Market Share Forecast by Application, 2022, 2032 (%)
Figure 30 Hepatitis Market Forecast by Region, 2022-2032 (US$ billion)
Figure 31 Hepatitis Market Share Forecast by Region, 2022 & 2032 (%)
Figure 32 HIV Market Forecast by Region, 2022-2032 (US$ billion)
Figure 33 HIV Market Share Forecast by Region, 2022 & 2032 (%)
Figure 34 Influenza Market Forecast by Region, 2022-2032 (US$ billion)
Figure 35 Influenza Market Share Forecast by Region, 2022 & 2032 (%)
Figure 36 Herpes Market Forecast by Region, 2022-2032 (US$ billion)
Figure 37 Herpes Market Share Forecast by Region, 2022 & 2032 (%)
Figure 38 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 39 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 40 Antiviral Drugs Market Forecast by End-users Segment: Market Attractiveness Index
Figure 41 Antiviral Drugs Market Share Forecast by End-users, 2022, 2032 (%)
Figure 42 Hospitals Market Forecast by Region, 2022-2032 (US$ billion)
Figure 43 Hospitals Market Share Forecast by Region, 2022 & 2032 (%)
Figure 44 Clinics Market Forecast by Region, 2022-2032 (US$ billion)
Figure 45 Clinics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 46 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 47 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 48 Antiviral Drugs Market Forecast by Age Group Segment: Market Attractiveness Index
Figure 49 Antiviral Drugs Market Share Forecast by Age Group, 2022, 2032 (%)
Figure 50 Adult Market Forecast by Region, 2022-2032 (US$ billion)
Figure 51 Adult Market Share Forecast by Region, 2022 & 2032 (%)
Figure 52 Geriatrics Market Forecast by Region, 2022-2032 (US$ billion)
Figure 53 Geriatrics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 54 Pediatrics Market Forecast by Region, 2022-2032 (US$ billion)
Figure 55 Pediatrics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 56 Antiviral Drugs Market Forecast by Type Segment: Market Attractiveness Index
Figure 57 Antiviral Drugs Market Share Forecast by Type, 2022, 2032 (%)
Figure 58 Branded Drugs Market Forecast by Region, 2022-2032 (US$ billion)
Figure 59 Branded Drugs Market Share Forecast by Region, 2022 & 2032 (%)
Figure 60 Generic Drugs Market Forecast by Region, 2022-2032 (US$ billion)
Figure 61 Generic Drugs Market Share Forecast by Region, 2022 & 2032 (%)
Figure 62 Antiviral Drugs Market Forecast by Region 2022 v.s. 2032 (Revenue, CAGR %)
Figure 63 Antiviral Drugs Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 64 Antiviral Drugs Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%))
Figure 65 North America Antiviral Drugs Market Attractiveness Index
Figure 66 North America Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 67 North America Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 68 North America Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 69 North America Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 70 North America Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 71 North America Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 72 North America Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 73 North America Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 74 North America Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 75 North America Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 76 North America Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 77 North America Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 78 North America Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 79 U.S. Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 80 Canada Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 81 Europe Antiviral Drugs Market Attractiveness Index
Figure 82 Europe Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 83 Europe Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 84 Europe Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 85 Europe Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 86 Europe Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 87 Europe Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 88 Europe Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 89 Europe Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 90 Europe Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 91 Europe Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 92 Europe Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 93 Europe Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 94 Europe Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 95 Germany Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 96 U.K. Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 97 France Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 98 Italy Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 99 Spain Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 100 Russia Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 101 Rest of Europe Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 102 Asia Pacific Antiviral Drugs Market Attractiveness Index
Figure 103 Asia Pacific Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 104 Asia Pacific Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 105 Asia Pacific Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 106 Asia Pacific Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 107 Asia Pacific Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 108 Asia Pacific Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 109 Asia Pacific Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 110 Asia Pacific Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 111 Asia Pacific Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 112 Asia Pacific Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 113 Asia Pacific Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 114 Asia Pacific Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 115 Asia Pacific Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 116 China Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 117 Japan Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 118 India Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 119 Australia Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 120 South Korea Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 121 Rest of Asia Pacific Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 122 Latin America Antiviral Drugs Market Attractiveness Index
Figure 123 Latin America Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 124 Latin America Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 125 Latin America Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 126 Latin America Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 127 Latin America Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 128 Latin America Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 129 Latin America Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 130 Latin America Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 131 Latin America Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 132 Latin America Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 133 Latin America Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 134 Latin America Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 135 Latin America Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 136 Brazil Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 137 Mexico Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 138 Rest of Latin America Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 139 Middle East & Africa Antiviral Drugs Market Attractiveness Index
Figure 140 Middle East & Africa Antiviral Drugs Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 141 Middle East & Africa Antiviral Drugs Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 142 Middle East & Africa Antiviral Drugs Market Share Forecast by Country, 2022 & 2032 (%)
Figure 143 Middle East & Africa Antiviral Drugs Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 144 Middle East & Africa Antiviral Drugs Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 145 Middle East & Africa Antiviral Drugs Market Forecast by Application, 2022-2032 (US$ billion, AGR %)
Figure 146 Middle East & Africa Antiviral Drugs Market Share Forecast by Application, 2022 & 2032 (%)
Figure 147 Middle East & Africa Antiviral Drugs Market Forecast by End-users, 2022-2032 (US$ billion, AGR %)
Figure 148 Middle East & Africa Antiviral Drugs Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 149 Middle East & Africa Antiviral Drugs Market Forecast by Age Group, 2022-2032 (US$ billion, AGR %)
Figure 150 Middle East & Africa Antiviral Drugs Market Share Forecast by Age Group, 2022 & 2032 (%)
Figure 151 Middle East & Africa Antiviral Drugs Market Forecast by Type, 2022-2032 (US$ billion, AGR %)
Figure 152 Middle East & Africa Antiviral Drugs Market Share Forecast by Type, 2022 & 2032 (%)
Figure 153 GCC Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 154 South Africa Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 155 Rest of Middle East & Africa Antiviral Drugs Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 157 Johnson & Johnson Services Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 158 Johnson & Johnson Services Inc. : Regional Revenue Shares, 2021
Figure 159 Johnson & Johnson Services Inc. : Segmental Revenue Shares, 2021
Figure 160 Merck KGaA : Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 161 Merck KGaA : Regional Revenue Shares, 2021
Figure 162 Merck KGaA : Segmental Revenue Shares, 2021
Figure 163 GlaxoSmithKline plc. : Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 164 GlaxoSmithKline plc. : Regional Revenue Shares, 2021
Figure 165 GlaxoSmithKline plc. : Segmental Revenue Shares, 2021
Figure 166 Novartis AG: Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 167 Novartis AG: Regional Revenue Shares, 2021
Figure 168 Novartis AG: Segmental Revenue Shares, 2021
Figure 169 F. Hoffmann-La Roche Ltd : Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 170 F. Hoffmann-La Roche Ltd : Regional Revenue Shares, 2021
Figure 171 F. Hoffmann-La Roche Ltd : Segmental Revenue Shares, 2021
Figure 172 AstraZeneca: Net Revenue, 2017-2021 (US $ million, AGR %)
Figure 173 AstraZeneca: Regional Revenue Shares, 2021
Figure 174 Bristol-Myers Squibb Company: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 175 Bristol-Myers Squibb Company: Regional Revenue Shares, 2021
Figure 176 AbbVie Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 177 AbbVie Inc.: Product Revenue Shares, 2021
Figure 178 AbbVie Inc.: Regional Revenue Shares, 2021
Figure 179 Gilead Sciences, Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 180 Gilead Sciences, Inc.: Product Revenue Shares, 2021
Figure 181 Gilead Sciences, Inc.: Regional Revenue Shares, 2021
Figure 182 Boehringer Ingelheim International GmbH : Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 183 Boehringer Ingelheim International GmbH Product Revenue Shares, 2021
Figure 184 Boehringer Ingelheim International GmbH: Regional Revenue Shares, 2021
Figure 185 Cipla: Product Revenue Shares, 2021
Figure 186 Abbott: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 187 Abbott: Product Revenue Shares, 2021
Figure 188 Abbott: Regional Revenue Shares, 2021
Figure 189 Viatris: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 190 Viatris: Regional Revenue Shares, 2021
Figure 191 Sun Pharmaceutical Industries Ltd. : Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 192 Sun Pharmaceutical Industries Ltd.: Regional Revenue Shares, 2021
Figure 193 Aurobindo Pharma: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 194 Dr. Reddy’s Laboratories Ltd. : Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 195 Dr. Reddy’s Laboratories Ltd. : Product Revenue Shares, 2021
Figure 196 Antiviral Drugs Market Share Forecast by Region, 2022, 2026, 2032 (%)

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

Visiongain社の医薬・化学品分野での最新刊レポート

本レポートと同じKEY WORD（covid19）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

抗ウイルス剤市場レポート：2022-2032

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療）の最新刊レポート

Visiongain社の医薬・化学品分野での最新刊レポート

本レポートと同じKEY WORD（covid19）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?